Compile Data Set for Download or QSAR
Report error Found 68 Enz. Inhib. hit(s) with all data for entry = 5564
TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370148BDBM370148(US20260021085, Compound 5)
Affinity DataIC50: 84nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372275BDBM372275(Synthesis of (1S,2R)-2-(((R)-(3-fluoro-4-isopropyl...)
Affinity DataIC50: 166nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 369917BDBM369917(US20260021085, Compound 4)
Affinity DataIC50: 178nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372281BDBM372281(US20260021085, Compound 28)
Affinity DataIC50: 224nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372271BDBM372271(US20260021085, Compound 19)
Affinity DataIC50: 228nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372291BDBM372291(US20260021085, Compound 37)
Affinity DataIC50: 236nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372260BDBM372260(US20260021085, Compound 8)
Affinity DataIC50: 239nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370178BDBM370178(US20260021085, Compound 6)
Affinity DataIC50: 272nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372299BDBM372299(US20260021085, Compound 45)
Affinity DataIC50: 364nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372270BDBM372270(US20260021085, Compound 18)
Affinity DataIC50: 384nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372294BDBM372294(US20260021085, Compound 40)
Affinity DataIC50: 390nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 369907BDBM369907(US20260021085, Compound 2)
Affinity DataIC50: 426nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372288BDBM372288(US20260021085, Compound 34)
Affinity DataIC50: 426nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372267BDBM372267(US20260021085, Compound 15)
Affinity DataIC50: 497nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 369908BDBM369908(US20260021085, Compound 3)
Affinity DataIC50: 630nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372295BDBM372295(US20260021085, Compound 41)
Affinity DataIC50: 637nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372279BDBM372279(US20260021085, Compound 26)
Affinity DataIC50: 795nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372268BDBM372268(US20260021085, Compound 16)
Affinity DataIC50: 836nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372290BDBM372290(US20260021085, Compound 36)
Affinity DataIC50: 837nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372261BDBM372261(US20260021085, Compound 9)
Affinity DataIC50: 879nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 370378BDBM370378(Synthesis of (1S,2R)-2-(((R)-(3-fluoro-4-isopropyl...)
Affinity DataIC50: 884nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372296BDBM372296(US20260021085, Compound 42)
Affinity DataIC50: 961nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372266BDBM372266(US20260021085, Compound 14)
Affinity DataIC50: 1.01E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372285BDBM372285(US20260021085, Compound 31)
Affinity DataIC50: 1.09E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372292BDBM372292(US20260021085, Compound 38)
Affinity DataIC50: 1.13E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372278BDBM372278(US20260021085, Compound 25)
Affinity DataIC50: 1.15E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372274BDBM372274(US20260021085, Compound 22)
Affinity DataIC50: 1.27E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 369880BDBM369880(US20260021085, Compound 1)
Affinity DataIC50: 1.44E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372280BDBM372280(US20260021085, Compound 27)
Affinity DataIC50: 1.48E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372282BDBM372282(US20260021085, Compound 29)
Affinity DataIC50: 1.52E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372269BDBM372269(US20260021085, Compound 17)
Affinity DataIC50: 1.58E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372284BDBM372284(US20260021085, Compound 30)
Affinity DataIC50: 1.61E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372264BDBM372264(US20260021085, Compound 12)
Affinity DataIC50: 1.73E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372263BDBM372263(US20260021085, Compound 11)
Affinity DataIC50: 1.95E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372273BDBM372273(US20260021085, Compound 21)
Affinity DataIC50: 1.96E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372265BDBM372265(US20260021085, Compound 13)
Affinity DataIC50: 2.36E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372272BDBM372272(US20260021085, Compound 20)
Affinity DataIC50: 2.38E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372286BDBM372286(US20260021085, Compound 32)
Affinity DataIC50: 2.39E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372289BDBM372289(US20260021085, Compound 35)
Affinity DataIC50: 2.40E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372276BDBM372276(US20260021085, Compound 24)
Affinity DataIC50: 2.82E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372262BDBM372262(US20260021085, Compound 10)
Affinity DataIC50: 2.93E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372287BDBM372287(US20260021085, Compound 33)
Affinity DataIC50: 3.13E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372293BDBM372293(US20260021085, Compound 39)
Affinity DataIC50: 3.41E+3nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, liver/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372281BDBM372281(US20260021085, Compound 28)
Affinity DataIC50: 7.80E+3nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, liver/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372275BDBM372275(Synthesis of (1S,2R)-2-(((R)-(3-fluoro-4-isopropyl...)
Affinity DataIC50: 8.48E+3nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, liver/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372294BDBM372294(US20260021085, Compound 40)
Affinity DataIC50: 1.08E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, liver/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372298BDBM372298(US20260021085, Compound 44)
Affinity DataIC50: 1.17E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372298BDBM372298(US20260021085, Compound 44)
Affinity DataIC50: 1.29E+4nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, liver/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372279BDBM372279(US20260021085, Compound 26)
Affinity DataIC50: 1.55E+4nMAssay Description:Compounds that inhibit the hGYS2 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

TargetGlycogen [starch] synthase, muscle/Glycogenin-1 (GN1)(Human)
Maze Therapeutics

US Patent
LigandChemical structure of BindingDB Monomer ID 372297BDBM372297(US20260021085, Compound 43)
Affinity DataIC50: 1.98E+4nMAssay Description:Compounds that inhibit the hGYS1 enzyme and, subsequently, the downstream conversion of NADH to NAD+, were tested using assay ready plates (black, cl...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/3/2026
Entry Details
US Patent

Displayed 1 to 50 (of 68 total ) | Next | Last >>
Jump to: